Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Analysis Highlights Growth To $8.66 Billion By 2030 At 4.3% CAGR

The Business Research Company’s Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Analysis Highlights Growth To $8.66 Billion By 2030 At 4.3% CAGR

LONDON, GREATER LONDON, UNITED KINGDOM, August 13, 2026 /EINPresswire.com/ — “The lateral flow immunoassay (LFIA) based rapid test market has been steadily developing over recent years, adapting to the growing demand for quick and accessible diagnostic solutions. As healthcare continues to embrace rapid testing technologies, this market is set to experience consistent growth driven by several key factors and evolving industry trends. Let’s explore the current market size, growth drivers, prominent regions, and underlying trends shaping the future of LFIA-based rapid tests.

Market Size and Growth Projections for the Lateral Flow Immunoassay (LFIA) Based Rapid Test Market
The LFIA-based rapid test market is projected to expand gradually, increasing from $7.17 billion in 2025 to $7.31 billion in 2026, with a compound annual growth rate (CAGR) of 2.0%. This steady growth during the historical period is largely due to the rising use of rapid infectious disease screening, wider adoption of pregnancy and fertility tests, the growth of point-of-care diagnostic tools, availability of affordable rapid tests, and the expansion of public health screening programs. Looking ahead, the market is expected to continue growing and reach $8.67 billion by 2030, accelerating at a CAGR of 4.3%. This forecasted growth is supported by increasing investments in decentralized diagnostics, the expansion of self-testing markets, higher demand for rapid cardiac and toxicology tests, enhanced integration with digital health platforms, and a stronger focus on early disease detection methods.

Download a free sample of the lateral flow immunoassay (lfia) based rapid test market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3293&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Aug_PR

Understanding the Role and Function of LFIA-Based Rapid Tests
Lateral flow immunoassay-based rapid tests are simple diagnostic devices designed to detect specific targets such as pathogens or biomarkers in bodily samples. These samples can include a variety of fluids like blood, urine, saliva, sweat, and others collected from patients. The ease and speed of these tests make them a preferred method for quick diagnostics in various healthcare settings.

Primary Factors Fueling Growth in the LFIA-Based Rapid Test Market
A significant force driving the LFIA rapid test market is the rising prevalence of chronic diseases worldwide. Chronic or non-communicable diseases (NCDs) are long-lasting health conditions that often require ongoing management. LFIA tests are highly valued in this context because they provide early detection, point-of-care testing, fast results, enable regular monitoring, and help reduce overall healthcare costs associated with managing chronic illnesses. These rapid tests empower both medical professionals and patients to make timely decisions regarding treatment and lifestyle adjustments. For instance, in June 2024, the UK’s National Health Service reported that 3,615,330 people registered with general practitioners were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase from 3,065,825 cases in 2022. This growing burden of chronic conditions is a key contributor to the rising demand for LFIA-based diagnostics.

View the full lateral flow immunoassay (lfia) based rapid test market report:
https://www.thebusinessresearchcompany.com/report/lateral-flow-immunoassay-based-rapid-test-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Aug_PR

Additional Drivers Encouraging LFIA Market Expansion
Beyond chronic disease management, the broader adoption of point-of-care testing and increased public health initiatives for infectious disease screening also support market growth. The availability of low-cost rapid tests makes these diagnostics accessible to a wider population, further boosting market penetration. Increasing awareness among consumers and healthcare providers about the benefits of rapid, easy-to-use tests continues to push the LFIA market forward.

Regional Market Leadership and Growth Outlook
In 2025, North America held the largest share of the LFIA-based rapid test market, reflecting the region’s advanced healthcare infrastructure and widespread use of point-of-care technologies. Meanwhile, the Asia-Pacific region is anticipated to be the fastest-growing market throughout the forecast period, driven by expanding healthcare access, increasing investments in diagnostic technologies, and growing demand for self-testing solutions. The market report covers key regions, including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a comprehensive overview of global market dynamics.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: marketing@tbrc.info

The Business Research Company – www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company“

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Media gallery